Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation

Transplant Infectious Disease

Volumn 7, Issue 3-4, 2005, Pages 137-145

  Koldehoff, Michael ^a,b   Elmaagacli, A H ^a   Steckel, N K ^a   Trenschel, R ^a   Hlinka, M ^a   Ditschkowski, M ^a   Beelen, D W ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Acute respiratory failure; Artificial ventilation; Fungal infection; Hematopoietic stem cell transplantation; Tracheotomy

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMIKACIN; AMPHOTERICIN B; CASPOFUNGIN; CEFTAZIDIME; CEFTRIAXONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCLOXACILLIN; FLUCONAZOLE; IMATINIB; IMIPENEM; NETILMICIN; PREDNISOLONE; RECOMBINANT INTERFERON; VANCOMYCIN; VORICONAZOLE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANAMNESIS; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL OBSERVATION; COMPARATIVE STUDY; DISEASE COURSE; DRUG SUBSTITUTION; EXTUBATION; FEBRILE NEUTROPENIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; LIVER TOXICITY; LUNG MYCOSIS; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RESPIRATORY FAILURE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TACHYCARDIA;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUNG DISEASES, FUNGAL; MIDDLE AGED; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 29544444223     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2005.00115.x     Document Type: Article

References (42)

1. PATTERSON TF. Advances and challenges in management of invasive mycoses. Lancet 2005: 366: 1013-1025.
2. KIBBLER C. Defining invasive fungal infections in neutropenic or stem cell transplant patients. J Antimicrob Chemother 2005: 56: i12-i16.
3. POUND MW, DREW RH, PERFECT JR. Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. Curr Opin Infect Dis 2002: 15: 183-194.
4. HAMZA NS, GHANNOUM MA, LAZARUS HM. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recpients. Bone Marrow Transplant 2004: 34: 377-389.
5. WINGARD JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999: 5: 55-68.
6. MARTINO R, SUBIRA M, ROVIRA M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002: 116: 475-482.
7. SOUBANI A, MILLER K, HASSOUN P. Pulmonary complications of bone marrow transplantation. Chest 1996: 109: 1066-1077.
8. CORNELY OA, ULLMANN AJ, KARTHAUS M. Evidence-baced assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003: 101: 3365-3372.
9. BARNES RA, STALLARD N. Severe infections after bone marrow transplantation. Curr Opin Crit Care 2001: 7: 362-366.
10. BACH PB, SCHRAG D, NIERMAN DM, et al. Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood 2001: 98: 3234-3240.
11. HUARINGA AJ, LEYVA FJ, GIRALT SA, et al. Outcome of bone marrow transplantation patients requiring mechanical ventilation. Crit Care Med 2000: 28: 1014-1017.
12. RUBENFELD GD, CRAWFORD SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med 1996: 125: 625-633.
13. WALD A, LEIDENRING W, VAN BURIK JA, BOWDEN RA. Epidemiology of aspergillus infection in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997: 175: 1459-1466.
14. MARR KA, BOWDEN RA. Fungal infections in patients undergoing blood and marrow transplantation. Transpl Infect Dis 1999: 1: 237-246.
15. OSTROSKY-ZEICHNER L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003: 16: 533-537.
16. ABI-SAID D, ANAISSIE E, UZUN O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997: 24: 1122-1128.
17. RICHARDSON MD. Changing patterns and trends in systemic fungal infection. J Antimicrob Chemother 2005: 56 (Suppl): i5-i11.
18. PAPPAS PG, REX JH, SOBEL JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004: 38: 161-189.
19. NICHOLS WG. Management of infectious complication in the hematopoietic stem cell transplant recipient. J Intensive Care Med 2003: 18: 295-312.
20. MARK KA, CARTER RA, CRIPPA F, WALD A, COREY L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002: 34: 909-917.
21. GHOSH K, RAFIQUE B, TIRKEY J, et al. Successful non-invasive ventilatory support in a patient with regimen-related toxicity during allogeneic bone marrow transplantation. Bone Marrow Transplant 1999: 23: 833-834.
22. KOLDEHOFF M, ZAKRZEWSKI JL. Modern management of respiratory failure due to pulmonary mycoses following allogeneic hematopoietic stem-cell transplantation. Am J Hematol 2005: 79: 158-163.
23. ASCIOGLU S, REX JH, DE PAUW B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002: 34: 7-14.
24. FRANQUET T, MULLER NL, LEE KS, OIKONOMOU A, FLINT JD. Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings. Radiology 2005: 236: 332-337.
25. FRANQUET T, MULLER NL, GIMENEZ A, et al. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics 2001: 21: 825-837.
26. VERWEIJ PE, MEIS JF. Microbiological diagnosis of invasive fungal infections in transplant recipients. Transpl Infect Dis 2000: 2: 80-87.
27. SENDID B, POIROT JL, TABOURET M, et al. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 2002: 51: 433-442.
28. MAERTENS J, VERHAEGEN J, LAGROU K, VAN ELDERE J, BOOGAERTS M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001: 97: 1604-1610.
29. MCLINTOCK LA, JONES BL. Advances in molecular and serological diagnosis of invasive fungal infection in haematooncology patients. Br J Haematol 2004: 126: 289-297.
30. PINEL C, FRICKER-HIDALGO H, LEBEAU B, et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003: 41: 2184-2186.
31. MACINTYRE NR, COOK DJ, ELY EW Jr, et al. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 2001: 120: 375S-395S.
32. HEFFNER JE. The role of tracheotomy in weaning. Chest 2001: 120: 477S-481S.
33. JAEGER JM, LITTLEWOOD KA, DURBIN CG Jr. The role of tracheostomy in weaning from mechanical ventilation. Respir Care 2002: 47: 469-480.
34. PIERSON DJ. Tracheostomy and weaning. Respir Care 2005: 50: 526-533.
35. HERBRECHT R, NATARAJAN-AME S, NIVOIX Y, LETSCHER-BRU V. The lipid formulation of amphotericin B. Expert Opin Pharmacother 2003: 4: 1277-1287.
36. OSTROSKY-ZEICHNER L, MARR KA, REX JH, COHEN SH. Amphotericin B: time for a new "gold standard." Clin Infect Dis 2003: 37: 415-425.
37. WALSH TJ, FINBERG RW, ARNDT C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999: 340: 764-771.
38. BAGG J, SWEENEY MP, LEWIS MA, et al. High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. Palliat Med 2003: 17: 477-481.
39. CHIOU CC, GROLL AH, WALSH TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000: 5: 120-135.
40. WALSH TJ, PAPPAS P, WINSTON DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002: 346: 225-234.
41. HERBRECHT R, DENNING DW, PATTERSON TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002: 347: 408-415.
42. TRENSCHEL R, DITSCHKOWSKI M, ELMAAGACLI AH, et al. Caspofungin as second-line therapy for fever of unkown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 2005: 35: 583-586.